Amir A. Tahami Monfared, MD PhD
Primary tabs
JAD profile
Associate Editor
Term Expiration:
12/31/2024
Affiliation(s):
Eisai Inc.
ORCID URL:
Areas of Interest:
Alzheimer's disease, amyloid, Disease-Modifying Therapies, modeling, Simulation, epidemiology
Biography & Research:
Amir A. Tahami, M.D., M.Sc., Ph.D., serves as the Global Value & Access Head for Alzheimer’s Disease and Brain Health (ADBH) at Eisai Inc. In this role, he leads and oversees a team responsible for developing and implementing the company’s global market access strategies, health economics and outcomes research, pricing, innovative contracting, and funding solutions for Neurology therapies in the company’s pipeline.
With over 15 years of experience in the pharmaceutical industry, Dr. Tahami has led global and national teams in defining, developing, and delivering clinical and economic value to stakeholders during early- and late-stage product development. He is dedicated to improving patient care through translating research outcomes into clinical practice and supporting informed decision-making and health policy. Dr. Tahami has been instrumental in the development, launch, and commercialization of over 20 medicines, including multiple blockbusters, across diverse therapeutic areas such as immuno-oncology, immunology, cardiovascular, diabetes, neuroscience, and infectious diseases.
Dr. Tahami is a distinguished physician-scientist and clinical epidemiologist, currently serving as an adjunct professor of Clinical Epidemiology at McGill University and Health Administration at New York University.
